TrialSignal
Clinical trial intelligence report
A Multicenter, Randomized, Double-Blind, Phase 3 Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT00676650
Status
TERMINATED
Phase
PHASE 3
Sponsor
Pfizer
Executive brief
Investment-Ready Snapshot
This clinical trial aimed to evaluate the efficacy and safety of sunitinib combined with prednisone in patients with metastatic castration-resistant prostate cancer who had previously failed docetaxel chemotherapy. The study was terminated early due to futility, indicating that the combination did not demonstrate sufficient efficacy compared to the control.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00676650
Indication
Prostatic Neoplasms
Modality
small molecule
Target
Metastatic Castration-Resistant Prostate Cancer
Intervention
Prednisone, sunitinib, Placebo, Prednisone
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.